LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Fermé

13.88 0.36

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.73

Max

13.88

Chiffres clés
By Trading Economics
Revenu	-6.4M -20M
Ventes	-807K 71M
BPA	-0.13
Marge bénéficiaire	-28.24
Employés	624
EBITDA	-7.9M -14M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+45.32% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-282M 2B
Ouverture précédente	13.52
Clôture précédente	13.88

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mai 2026, 22:26 UTC

Acquisitions, Fusions, Rachats

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mai 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mai 2026, 22:23 UTC

Acquisitions, Fusions, Rachats

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 21:10 UTC

Résultats

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 mai 2026, 19:47 UTC

Résultats

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mai 2026, 18:35 UTC

Acquisitions, Fusions, Rachats

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

45.32% hausse

Prévisions sur 12 Mois

Moyen 20.17 USD 45.32%

Haut 22 USD

Bas 18 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.